tirzepatide cnn The end of a shortage of popular weight-loss drugs may mean many people lose access to them Read now: The SURPASS-EARLY trial

Novo Nordisk has highlighted strong early uptake for its obesity pill in the US in early 2026 , framing oral semaglutide in obesity as part of its growth strategy beyond injectables

Note: Bookings can only be cancelled or rescheduled up to 48 hours before the scheduled appointment time

People with alcohol use disorder and obesity drank less when treated with a GLP-1 drug in addition to cognitive behavioral therapy.

Many people taking SSRIs for depression or anxiety wonder if GLP-1 weight loss medications are safe to use alongside their current antidepressants

Andy Wertheim discusses the growing shortage of available manufacturing capacity driven by the boom in GLP-1 therapies, why this means mid-volume development programmes across a range of sectors are struggling to move from development to industrialisation, and how Quvara Medical is ideally positioned to provide the capacity that these programmes lack.

Semaglutide has emerged as a potent force in the realm of health and wellness, offering promising results in weight management.